Dr. Sumit Mukherjee M.D.

Recommended Articles

• New Study May Explain Mucus Issues in People with CF

  As someone with cystic fibrosis, you probably sometimes have difficulty breathing. You may even know that the cause of the trouble most often relates to the mucus in your lungs. It is a clear, green or yellow slime which causes intense aggravation. In the case of people with cystic fibrosis, it can...

• Pleurisy vs. Bronchitis: Differences and Similarities

  What is pleurisy?Pleurisy is a condition, in which the lining that surrounds the lungs and the interior of the chest cavity is inflamed. Due to the inflammation of the pleura, this condition is also called as pleuritis. The pleural space is the space between the lungs and the chest cavity wall....

• How Do Cystic Fibrosis Clinical Trials Work?

  The great thing about medical research is that there are always new clinical trials going on in an attempt to find a cure, or at least new treatment options. However, it can be confusing to understand what actually goes on in these trials, and how they come about in the first place. Read further to...

• Procedure Found to Help Children with Cystic Fibrosis

  Researchers have recently found that the simple procedure of inhaling hypertonic saline solution, or HSS, can increase sputum production and improve pathogen identification in children. This breakthrough will act as a benefit to many suffering from cystic fibrosis who are unable to spontaneously...

• Doctor Turns Personal Tragedy Into Fight Against Cystic Fibrosis

  Since cystic fibrosis runs in the family, continuously researching news about the disease can help both patients and their families stay up to date on current events, such as new CF medications and treatments. Yet, for one woman, Dr. Wanda O’Neal, merely researching the latest information on CF...

• FDA Approves Orkambi to Treat Young Children with Cystic Fibrosis

  Orkambi is an oral drug developed by Vertex Pharmaceuticals and approved by the United States Food and Drug Administration (FDA) for the treatment of cystic fibrosis (CF) in certain patient groups. It is the second drug to be approved for use in patients with CF, after Kalydeco. ...